Hong Kong Industry Works With Regulator To Ensure Open Market Stays Open
This article was originally published in PharmAsia News
Major changes are afoot in Hong Kong’s drug approval and regulatory process with safety a prime focus following a series of reforms implemented last year in response to six deaths from spurious generic drugs in 2009.
You may also be interested in...
AstraZeneca Hong Kong President Sian Ng On The Pros And Cons Of The Hong Kong Market: An Interview With PharmAsia News
Hong Kong is increasingly viewed, and judged, in the shadow of Mainland China, which has seen explosive growth in recent years and has become the top emerging markets priority for most Big Pharma. This perception, however, obscures the reality that Hong Kong remains an independent and vibrant market, where new drugs are often approved more quickly than on the mainland.
HONG KONG - Hong Kong regulators may step up inspections of drug manufacturing facilities outside the former British enclave following a series of recommendations in December to improve drug safety
Hong Kong Pharmaceutical Industry Association Executive Director Sabrina Chan On Competition and R&D in Hong Kong: An Interview with PharmAsia News (Part 1 of 2)
Hong Kong, with a population of just under 7 million and long known for its status as one of the most open markets in the world, can be a challenging market for pharma companies because roughly half of the drugs sold in the Special Administrative Region of China go through its Hospital Authority. It can take up to three years to get an approved product on its list of available products. The Hong Kong Pharmaceutical Industry Association, which represents 42 companies including multinational companies that operate in Hong Kong, is fighting to cut through the red tape and get innovative drugs to patients faster while trying to stay on top of a stubborn counterfeit problem, Executive Director Sabrina Chan told PharmAsia News' Hong Kong Bureau in an exclusive interview.